Press coverage about Validus (NYSE:VR) has trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Validus earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned news articles about the insurance provider an impact score of 45.6055256417729 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
- The Law Offices of Vincent Wong Notifies Investors of an Investigation of Validus Holdings, Ltd. in Connection with the Sale of the Company to American International Group, Inc. (finance.yahoo.com)
- Validus Holdings Ltd.: Validus Holdings, Ltd. Cancels Fourth Quarter and Year End 2017 Financial Results Conference Call and Webcast (twst.com)
- Validus Target of Unusually High Options Trading (VR) (americanbankingnews.com)
Shares of Validus (NYSE:VR) traded up $0.26 on Wednesday, reaching $67.70. The company’s stock had a trading volume of 2,240,000 shares, compared to its average volume of 2,100,000. Validus has a 12 month low of $41.15 and a 12 month high of $67.73. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.52. The firm has a market cap of $5,380.00, a PE ratio of -104.15, a P/E/G ratio of 1.81 and a beta of 0.67.
A number of brokerages have commented on VR. ValuEngine raised Validus from a “sell” rating to a “hold” rating in a research report on Friday, October 20th. TheStreet cut Validus from a “b” rating to a “c+” rating in a research report on Wednesday, October 11th. Zacks Investment Research reaffirmed a “strong sell” rating on shares of Validus in a research report on Saturday, January 6th. Keefe, Bruyette & Woods cut Validus from an “outperform” rating to a “market perform” rating in a research report on Monday, January 22nd. Finally, UBS Group lifted their price target on Validus from $48.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, October 30th. Two analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $52.80.
In other Validus news, President Kean Driscoll sold 6,875 shares of Validus stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $46.16, for a total transaction of $317,350.00. Following the completion of the sale, the president now owns 110,858 shares of the company’s stock, valued at approximately $5,117,205.28. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have sold 20,625 shares of company stock valued at $984,775. 2.33% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This news story was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://transcriptdaily.com/2018/02/01/validus-vr-getting-somewhat-positive-media-coverage-report-finds.html.
Validus Holdings, Ltd. is a holding company. The Company operates through four segments: Validus Re, Talbot, Western World and AlphaCat. Validus Re is a Bermuda-based reinsurance segment focused treaty reinsurance. Validus Re concentrates on first-party property and other reinsurance risks. Talbot is a specialty insurance segment operating within the Lloyd’s insurance market through Syndicate 1183.
Receive News & Ratings for Validus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Validus and related companies with MarketBeat.com's FREE daily email newsletter.